Lawrence, Evans & Co., LLC
Lawrence, Evans & Co., LLC provides investment banking, corporate finance, and advisory services to lower-middle-market private companies. Its public focus includes healthcare providers, facilities, revenue-cycle management, health IT, and related healthcare services, alongside selected transportation, logistics, and business-services experience.
What stands out about Lawrence, Evans & Co., LLC
LECO publicly positions itself as a national boutique healthcare financial advisory firm offering sell-side and buy-side advisory, valuation, strategic-options analysis, financing, capital raising, and restructuring services. Its stated clients typically have under $250 million in revenues and may include distressed companies or startups.[1][2][3][4][6]
What does Lawrence, Evans & Co., LLC do?
Lawrence, Evans & Co., LLC, also referred to as LECO, is a national boutique healthcare financial advisory firm with an office in Columbus, Ohio. The firm provides investment banking, corporate finance, and advisory services to lower-middle-market private companies executing financial and strategic transactions.[1]
Publicly listed services include sell-side advisory, buy-side advisory, business valuation, and strategic-options analysis. LECO also advises on debt and equity capital raising, including senior debt, subordinate debt, unitranche, mezzanine, bridge loans, asset-based lines of credit, equipment financing, venture debt, growth capital, convertible debt, preferred equity, and private equity or family-office capital.[2][3]
Owners comparing advisory firms can also review Auxo’s M&A advisor vs. business broker vs. investment bank comparison, advisor-selection guide, and sell-side advisor evaluation framework.
What should a business owner evaluate before hiring Lawrence, Evans & Co., LLC?
An owner considering a sale or capital transaction would be evaluating a specialist boutique that publicly emphasizes healthcare and lower-middle-market companies, including distressed situations and startups. LECO states that it provides owner-oriented transaction advisory, valuation, and buyer-identification capabilities, while also offering financing and restructuring services.
The investment-banking advisory page does not publish a universal fee schedule, expense schedule, termination provision, or tail period, so proposed economics, reimbursable expenses, termination rights, and tail provisions should be confirmed directly. Owners may also wish to clarify the senior professionals assigned, the intended buyer or lender outreach, any financing or counterparty relationships, and the firm-level registrations applicable to the proposed services.[2][3][4]
What are the proposed retainer, success fee, reimbursable expenses, termination rights, and tail provisions
Which senior professionals would lead the mandate, and what comparable healthcare transactions can the firm identify
Does the firm or any affiliate provide financing, invest principal capital, or receive compensation from lenders, buyers, or other counterparties
What size transactions and clients does Lawrence, Evans & Co., LLC focus on?
LECO identifies healthcare providers, healthcare facilities, healthcare revenue-cycle management, health IT, data and analytics, transportation and logistics, and business services as areas of sector experience. Its described transaction experience also includes acute-care hospitals, senior housing, home health, behavioral health, revenue-cycle management, health IT, big data, analytics, life sciences, managed IT, and cybersecurity-related companies.[1][4]
The prior-engagements archive identifies a $10,000,000 Upper Midwest home-health-agency sale to a strategic buyer, a $7,500,000 Ohio home-infusion refinancing, a $35,000,000 Midwest skilled-nursing and assisted-living portfolio engagement, and a $70,000,000 Midwest specialty warehouse, brokerage, and trucking engagement.
The current-engagements page identifies Project Fuji, a healthcare cybersecurity and compliance company partnership or sale, as closed in May 2025, and Project CORE, a revenue-cycle-management and medical-billing acquisition opportunity, as closed in May 2025. Current publicly listed mandates include Project Wizard, an acquisition opportunity with $4.0 million of EBITDA; Project Pearl, a $25 million financing request; Project Haven, an acquisition opportunity with $15 million of revenues and $4 million of pro forma EBITDA; and Project Bull, a $30 million financing request.[5][6]
The firm’s public service offering covers sell-side and buy-side advisory, business valuation, strategic-options analysis, and debt and equity capital raising. The disclosed financing categories span senior and subordinate debt, unitranche, mezzanine, bridge loans, asset-based lines of credit, equipment financing, venture debt, growth capital, convertible debt, preferred equity, and private equity or family-office capital.[2][3]
What does Lawrence, Evans & Co., LLC publicly disclose about fees, process and engagement terms?
The investment-banking advisory page does not publish a universal fee schedule, minimum fee, success-fee percentage, expense schedule, termination provision, or tail period.
The current-engagements page generally presents mandates under project codenames and does not disclose client legal names, counterparties, or consideration terms for the listed mandates. The About Us page identifies the entity as an LLC and an advisory firm but does not establish a firm-level broker-dealer or investment-adviser registration status.[2][4][6]
The official website identifies the entity as Lawrence, Evans & Co., LLC and describes it as an investment-banking, corporate-finance, and advisory firm. The About Us page does not establish a firm-level broker-dealer or investment-adviser registration status.[4]
The current-engagements page generally presents mandates under project codenames. The listed mandates include acquisition opportunities and financing requests with selected revenue, EBITDA, or financing metrics.[6]
Questions to ask before hiring Lawrence, Evans & Co., LLC
What are the proposed retainer, success fee, reimbursable expenses, termination rights, and tail provisions?
Which senior professionals would lead the mandate, and what comparable healthcare transactions can the firm identify?
Does the firm or any affiliate provide financing, invest principal capital, or receive compensation from lenders, buyers, or other counterparties?
What buyer universe and outreach process would be used for a proposed sale?
What firm-level regulatory or legal-entity registrations apply to the proposed services?
Sources & research notes
- Official website / firm overview
- Services / capabilities
- Services / capabilities
- Industry / market focus
- Transaction / portfolio evidence
- Transaction / portfolio evidence
How this profile was researched
Auxo profiles are prepared from publicly available primary and authoritative sources and reviewed for entity identity, factual support and disclosure consistency. When a fact cannot be supported by the reviewed public record, the profile identifies it as something to confirm directly rather than inferring it.
Independent research profile
This profile was prepared by Auxo Capital Advisors from publicly available information believed to be reliable and is provided solely for informational and educational purposes. It is not an endorsement, recommendation, ranking, solicitation, or representation regarding the profiled firm, its services, qualifications, transaction experience, regulatory status, financial condition, or suitability for any particular person, company, transaction, or investment.
Information obtained from third-party and public sources may be incomplete, inaccurate, outdated, or subject to change, and Auxo Capital Advisors makes no representation or warranty, express or implied, as to its accuracy, completeness, or timeliness. Readers should conduct their own independent diligence and consult appropriate professional advisers before engaging any advisor, intermediary, investor, lender, acquirer, or other transaction counterparty.
Broker-dealer and securities disclosure
Auxo Capital Advisors is an affiliate of Weild & Co., Member FINRA | SIPC. Securities-related activities and securities transactions are conducted through Weild & Co.
Nothing contained on this page constitutes an offer to sell, an offer to purchase, or a solicitation of an offer to buy or sell any security, investment product, or financial instrument. Nothing on this page constitutes investment advice, a recommendation regarding any security, or a recommendation to enter into any transaction with the profiled firm or any other party.
Any securities transaction, capital-raising engagement, investment-banking engagement, or other securities-related activity involving Auxo Capital Advisors or Weild & Co. is subject to applicable regulatory requirements, internal review and approval, suitability and other applicable diligence requirements, and the terms of a separate written engagement or transaction agreement, as applicable.
Inclusion of a third-party firm in this directory does not imply affiliation with, sponsorship by, endorsement by, or any other relationship with Auxo Capital Advisors or Weild & Co. unless expressly stated otherwise.